Azelby Robert 4

What Happened

• Robert Azelby, a director of Autolus Therapeutics plc (AUTL), received two awards of restricted stock units (RSUs) on June 29, 2026 totaling 79,167 RSUs (31,667 and 47,500). Each award is recorded at $0.00 (no cash paid) and is reported as a derivative grant (contingent right to receive ADS/shares).

Key Details

• Transaction date: 2026-06-29; Transaction type/code: A (award/grant); price per unit reported: $0.00.
• Total RSUs granted: 79,167 (31,667 + 47,500).
• Vesting: RSUs vest in one installment on June 29, 2027 (footnote F2).
• Nature of the award: Each RSU is a contingent right to receive one American Depositary Share (ADS), and each ADS is convertible at the option of the holder into one ordinary share (footnote F1).
• Additional note: Filing references share options that vest in twelve equal monthly installments starting July 29, 2026 (footnote F3); those options are not detailed as separate grants in the reported RSU lines.
• Shares owned after the transaction: not specified in the provided filing.
• Timeliness: Report filed 2026-07-01 for a 2026-06-29 transaction (appears timely).

Context

• This was a compensation award (RSUs), not an open-market purchase or sale. RSU grants are common for executives and directors as part of pay/retention and do not by themselves indicate immediate buying or selling sentiment.
• As these are derivative awards, the actual shares/ADS will be delivered only if and when the RSUs vest (here, one year from grant).